Andrew J. Gunderson

Sep 4, 2024 | cell.com | Andrew J. Gunderson

Get full text accessLog in, subscribe or purchase for full access. References1. Tawbi, H.A. ∙ Schadendorf, D. ∙ Lipson, E.J. ... Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaN. Engl. J. Med. 2022; 386:24-342. Long, G.V. ∙ Stephen Hodi, F. ∙ Lipson, E.J. ... Overall Survival and Response with Nivolumab and Relatlimab in Advanced MelanomaNEJM Evid. 2023; 2, EVIDoa22002393. Ngiow, S.F. ∙ Manne, S. ∙ Huang, Y.J. ...

Aug 4, 2023 | mdpi.com | Andrew J. Gunderson |Shafia Rahman |Jordan M. Cloyd |Robert Connor Chick

Abstract: Simple SummaryPancreatic cancer is a deadly disease with limited effective treatments. Despite growing interest in immunotherapy for other cancer types, immunotherapy has not shown significant utility in metastatic pancreatic cancer. However, investigators are examining the role of immunotherapy in the preoperative setting in order to prime the immune system to detect and prevent micrometastatic disease and recurrence.

Jul 17, 2023 | frontiersin.org | Avishek Bhuniya |Srimoyee Mukherjee |Andrew J. Gunderson |Jianjun Gao

Xinlei Zou†, Canghai Guan†, Jianjun Gao, Wujiang Shi, Yunfu Cui and Xiangyu Zhong*Department of Hepatopancreatobiary Surgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, ChinaPancreatic cancer (PC) is extremely malignant and shows limited response to available immunotherapies due to the hypoxic and immunosuppressive nature of its tumor microenvironment (TME).